# OnCo record lapatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/lapatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "lapatinib" ;
  schema:name "Lapatinib"@en ;
  schema:description "Lapatinib was the first HER2-blocking pill (2007) and is now mostly a comparator arm and a late-line option, displaced by tucatinib and ADCs."@en ;
  schema:url <https://onco.cc/drugs/lapatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lapatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q420323> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lapatinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule reversible HER2/EGFR kinase inhibitor" ;
  schema:alternateName "Tykerb" ;
  onco:approval "US 2007: HER2+ advanced breast cancer with capecitabine after trastuzumab", "US 2010: HR+/HER2+ metastatic breast cancer with letrozole" ;
  onco:acceleratedApproval "US 2010-01-29: In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated" ;
  onco:acceleratedApprovalConfirmed "US 2018-12-06: In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-breast-brain-metastases/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:trials <https://onco.cc/trials/ace-breast-02/>, <https://onco.cc/trials/nct06313983/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/> .